Funding for this research was provided by:
Glaukos Corporation
Article History
Accepted: 8 November 2021
First Online: 10 December 2021
Declarations
:
: THEMA Consulting, owned by D.T., received consulting fees for this work from Glaukos Corporation, the manufacturer of iStent<sup>®</sup> and iStent inject<sup>®</sup>, as part of a reimbursement submission to the Australian Medical Services Advisory Committee (MSAC). Glaukos had no editorial input in the writing of this manuscript.
: D.T. is the Director and D.J. and L.A. are employees of THEMA Consulting, a health economics consultancy that received consulting fees from Glaukos Corporation for this work as part of a reimbursement submission to MSAC. P.H. has no direct competing interest but has in the past received honoraria from both Glaukos and Ivantis, who manufacture TBDs, and from Allergan and Novartis, who manufacture glaucoma drops.
: Not applicable.
: Not applicable.
: The data used in our analyses were taken from published or publicly available sources.
: The model files are available from the corresponding author on reasonable request.
: All authors contributed to the study conception and design. D.T., D.J. and L.A. contributed to identification and sourcing of inputs and the development of the economic model. P.H. contributed clinical expert opinion and review and revisions to the model, inputs and manuscript. All authors contributed to drafting, reviewing and approving the final manuscript.